Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Biguanides Market

Biguanides Market Share

Report ID: GMI8309
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Biguanides Market Share

The biguanides industry is characterized by a dynamic interplay among pharmaceutical companies striving to capture a significant share. Companies such as Merck & Co., Inc, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Ltd. are notable players, with well-established product portfolios. These players are constantly involved in strategic alliances, collaborations, and market expansion initiatives to strengthen their foothold in the market.

Biguanides Market Companies

Some of the key players operating in the biguanides industry include:

Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Ltd.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd.
Merck & Co., Inc.
Sanofi
Takeda Pharmaceutical Company Limited.
Teva Pharmaceuticals Industries Ltd.
Zydus Group

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global biguanides industry was valued at USD 5.2 billion in 2023 and is projected to grow at a CAGR of 2.9% between 2024 and 2032, attributed to the rising number of diabetes cases globally.

The branded biguanides segment held a business share of 87.4% in 2023 and is poised to grow rapidly through 2032, attributed to established reputation, patent protection, physician preference, perceived quality, and patient brand loyalty.

North America biguanides industry held a revenue share of 38.2% and is set to grow significantly through 2032, driven by the significant burden of diabetes in the region.

Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Merck & Co., Inc., Sanofi, Takeda Pharmaceutical Company Limited., Teva Pharmaceuticals Industries Ltd. are some of the major industry contenders.